Divalproex loading in the treatment of cocaine dependence.

Ralph H. Johnson VA Medical Center, Substance Abuse Treatment Center, Charleston, South Carolina 29401, USA.
Journal of psychoactive drugs (Impact Factor: 1.1). 01/2001; 33(3):283-7. DOI: 10.1080/02791072.2001.10400575
Source: PubMed

ABSTRACT The current pilot project was designed to evaluate the safety and tolerability of a loading dose of divalproex (DVPX) in subjects with cocaine dependence. Seventeen cocaine-dependent subjects were enrolled in an eight-week, open-label trial of 20 mg/kg/day DVPX. Subjects were seen weekly and urine drug screens were obtained at each visit. Over the eight-week trial, craving intensity and frequency as well as reported time using cocaine decreased significantly. Retention in the current study was 79% at week four and 50% at week eight. The medication and dosing strategy was well tolerated. This pilot study indicates that DVPX loading is well tolerated and may be efficacious in the treatment of cocaine dependence. A placebo-controlled trial would be of interest.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: To review evidence about mechanisms and consequences of relationships between bipolar and substance use disorders.
    Journal of Dual Diagnosis 11/2008; 1(3):9-23. DOI:10.1300/J374v01n03_03 · 0.80 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pathological gambling (PG) affects about 0.2-2% of adults and the impact extends to family members, employers and society as a whole. Recent research has identified similarities in the pathophysiologies of PG and substance use disorders (SUDs). As such, findings regarding SUDs provide a framework for investigating PG. The aims of the manuscript are two-fold. First, we will briefly revivew neural systems implicated in PG. Cortico-limbic circuitry involving the ventral striatum, ventromedial prefrontal cortex, anterior cingulate cortex, and dorsolateral prefrontal cortex are discussed as are the neurotransmitters norepinephrine, serotonin, dopamine, opioids, glutamate, and gamma-aminobutyric acid (GABA). This background will provide a framework for reviewing the psychopharmacological treatments that have been tested for efficacy and safety in treating PG. Of medications, the strongest data suggest the efficacy and tolerability of opioid antagonists in the treatment of PG, and other agents have varying degree of empirical support. As behavioral therapies have also shown efficacy, they will be briefly considered as well. Future research is needed to understand how treatments work in PG and for whom specific treatments might work best.
    02/2012; 1(1). DOI:10.2174/2211556011201010067
  • Source
    Psiquiatria Biologica 01/2003; 10(4):133-143.